Long-term cardiac reverse remodeling after cardiac resynchronization therapy

Belén Alvarez-Alvarez MD, PhD | Javier García-Seara MD, PhD | Jose L. Martínez-Sande MD, PhD | Moisés Rodríguez-Mañero MD, PhD | Xesús A. Fernández López MD | Laila González-Melchor MD | Diego Iglesias-Alvarez MD | Francisco Gude MD, PhD | Carla Díaz-Louzao | José R. González-Juanatey MD, PhD

1Cardiology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
2Arrhythmia Unit, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
3Epidemiology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
4Statistics and Biomedical Data Science Research Group (GRID-BDS), Department of Statistics, Mathematical Analysis and Optimization, University of Santiago de Compostela, Santiago de Compostela, Spain

Abstract

Introduction: The benefit of cardiac resynchronization therapy (CRT) in heart failure (HF) patients with reduced left ventricular ejection fraction (LVEF) have been observed in the first year. However, there are few data on long-term follow-up and the effect of changes of LVEF on mortality. This study aimed to assess the LV remodeling after CRT implantation and the probable effect of changes in LVEF with repeated measures on mortality over time in a real-world registry.

Methods: Among our cohort of 328 consecutive CRT patients, mixed model effect analysis have been made to describe the temporal evolution of LVEF and LVESV changes over time up with several explanatory variables. Besides, the effect of LVEF along time on the probability of mortality was evaluated using joint modeling for longitudinal and survival data.

Results: The study population included 328 patients (253 men; 70.2 ± 9.5 years) in 4.2 (2.9) years follow-up. There was an increase in LVEF of 11% and a reduction in LVESV of 42 mL during the first year. These changes are more important during the first year, but slight changes remain during the follow-up. The largest reduction in LVESV occurred in patients with left bundle branch block (LBBB) and the smallest reduction in patients with NYHA IV. The smallest increase in LVEF was an ischemic etiology, longer QRS, and LV electrode in a nonlateral vein. Besides, the results showed that the LVEF profiles taken during follow-up after CRT were associated with changes in the risk of death.

Conclusion: Reverse remodeling of the left ventricle is observed especially during the first year, but it seems to be maintained later after CRT implantation in a contemporary cohort of patients. Longitudinal measurements could give us additional information at predicting the individual mortality risk after adjusting by age and sex compared to a single LVEF measurement after CRT.

Keywords:
cardiac resynchronization therapy, heart failure, long-term follow-up, ventricular remodeling
1 | INTRODUCTION

Cardiac remodeling occurs due to abnormal neurohormonal regulation in heart failure (HF) patients. The principal feature of remodeling is left ventricular (LV) dilatation and deterioration of LV function. Major clinical trials have demonstrated the benefit of cardiac resynchronization therapy (CRT) in HF patients with reduced LVEF. It is well established for patients with left ventricular systolic dysfunction and ventricular conduction delay under optimal medical therapy. CRT has been shown to improve functional class, reduce hospitalization and mortality among patients with symptomatic HF, as well as LV reverse remodeling. The concept of cardiac reverse remodeling was developed to explain the reduction of LV volumes and improvements in LV function observed with the use of medical therapies for HF and CRT. Currently, the reduction of left ventricular end-systolic volume (LVESV) ≥15% and/or the increase in the absolute value of left ventricular ejection fraction (LVEF) ≥5% at 6-12 months have been identified as predictors of clinical prognosis and response to CRT. Evidence suggests that the improved outcomes observed with CRT are associated with reverse remodeling.

Up to date, randomized clinical trials of CRT have documented increases in LVEF and/or reduction in LV volumes in the first year after CRT implantation. However, there are scarce data on the mid-term and long-term benefit of this therapy and the sustained effect of ventricular remodeling over a prolonged follow-up period. In addition, it remains unknown the effect of LVEF on mortality over time. Here, we evaluate the long-term cardiac reverse remodeling after CRT in patients with repeated echocardiographic measurements in a contemporary patient registry and how changes in LVEF over time, with several measurements per patient, may better predict the individual risk of mortality.

2 | METHODS

This retrospective follow-up study includes 328 consecutive patients with cardiac resynchronization therapy—defibrillator (CRT-D) or pacemaker (CRT-P) under standard clinical indications in a single tertiary cardiac institution between January 2005 and April 2015. All the patients demonstrated HF symptoms (New York Heart Association—NYHA—functional class II, III or ambulatory IV symptoms), with ischemic or nonischemic cardiomyopathy, decreased LVEF (≤35%), and prolonged QRS duration (≥120 ms) at the time of implantation. They received pharmacological treatment for HF uptitrated to the maximal tolerated doses according to the European Society of Cardiology guidelines for the management of HF at the discretion of the treating cardiologist.

We registered the baseline characteristics of all of the patients. Electrocardiographic features included QRS width and morphology. Echocardiographic parameters included LV end-diastolic (LVEDV) and end-systolic volume (LVESV), LVEF, left atrial diameter (LAD), and mitral regurgitation. For the quantification of the severity of mitral regurgitation, the ratio between the maximum regurgitant jet obtained from the flow image by color doppler and the area of the left atrium was used. In cases of eccentric mitral regurgitation, the contracted vein was used for quantification. The patients were followed up in the Heart Failure Clinic every 3 or 6 months and in the CRT-Device Clinic every 6 months. Electrocardiogram and echocardiogram were also performed at the 6-month and 2-year follow-ups and according to the discretion of the HF cardiologist. Treating cardiologists followed a specified protocol to achieve OMT. Patients with decreases in LVESV exceeding 15% and/or improvements in LVEF of more than 5% were considered to be echocardiographic responders. Patients with improvements in one category in NYHA functional class were considered to be clinical responders.

This study was conducted in accordance with the Principles of the Declaration of Helsinki. The clinical study (2017/171) was initially approved in 2017 by the Clinical Research Ethics Committee (CEIC) of Galicia.

2.1 | Statistical analysis

Qualitative variables are expressed as frequency and percentages. Quantitative variables are presented as mean (SD) or as a median (interquartile range) as appropriate. The chi-square test X2 or U of Mann-Whitney was used to compare qualitative variables. P ≤ .05 was considered statistical significance.

Mixed effects models have been fitted to describe the relationship between echocardiographic changes (LVEF and LVESV) in the follow-up as a function of several explanatory covariates (age, sex, etiology, NYHA class, rhythm in the time of implantation, morphology, and duration of the baseline QRS, location of the electrode in the coronary sinus). These models contain both fixed and random effects, possibility of correlated data, and variability heterogeneous. They are particularly useful in settings where repeated measurements are made on the same units (longitudinal study). Besides, this model allows to deal with missing values.

Joint modeling for longitudinal and survival data was used to model the relationship between LVEF profiles over time and mortality. These models allow dynamic predictions of the risk of mortality of individuals updating and improving with every new longitudinal observation. All statistical analyses were performed with the software R (CRAN-R).

3 | RESULTS

3.1 | Patient characteristics

The study population included 328 patients (253 men and 75 women; mean age: 70.2 (9.5) years) who were consecutively implanted with a CRT device at our institution. The mean follow-up duration was
4.2 (2.9) years. Of the 328 patients, only 122 (37.2%) were on triple neurohormonal therapy at the time of implantation. The baseline characteristics are listed in Table 1.

### Baseline Echocardiographic Characteristics

The mean baseline LVEF was 28%. In our sample more than half of the patients had severe mitral regurgitation at the time of the CRT implant due to severe dilatation of the LV (182, 55.5%) and 13 (4.0%) did not present mitral regurgitation prior to CRT. LVESV and LVEDV were 156 (55) mL and 215 (64) mL respectively (Table 1).

### Mortality at Follow-up

The probability of survival at 1 year was 89.2%, at 5 years was 61.3% and at 10 years was 33.4%. Six patients were transplanted at 3 years after undergoing the CRT. During the first year of follow-up, 34 (10.4%) patients died; 55.9% were cardiovascular mortality, mostly due to heart failure (73.7%). The causes of mortality were: 44.0% (55) cardiovascular mortality (74.5% HF, 21.9% arrhythmias, 3.6% coronary syndromes), 30.4% (38) no cardiovascular mortality (60.5% infections, 21.1% neoplasia, 18.4% bleeding events), and 25.6% (32) other and unknown.

### Echocardiographic Characteristics at Follow-up

The echocardiogram was performed during the first year and then every 2 years, at the request of the responsible clinician or during the patient's clinical deterioration. At follow-up, a maximum of four measurements of the echocardiographic parameters were performed in patients with CRT. The first postimplant echocardiogram was obtained in 327 patients (one patient died during implant admission), the measurements of two echocardiograms were obtained in 181 patients, three measurements in 51 patients, and four measurements in 10 patients.

In the first year, LVEF increased by 11% and LVESV decreased by 42 mL. We have also identified that 68 patients (20.7%) presented normalization of the function and structure of the LV, associated with a better clinical prognosis. The changes in LVEF and LVESV profiles are observed especially during the first year, but improvements in LVEF and LVESV are not only maintained, but slightly increase in a longer follow-up (Figure 1). This may be influenced because patients who die are excluded, 10.4% died during the first year and 38.2% at the end of follow-up. Of them, 12 (3.7%) patients had sudden death.

Changes are observed during the first year in both sexes, but more marked in women than in men. It is also observed in patients with nonischemic cardiomyopathy. However, the response to CRT in patients with ischemic HF is unchanged in the long term. Patients in NYHA III class, and with LV lead located in posterior and lateral veins have better reverse remodeling of LV (Figures S1-S5).

### Table 1 Baseline characteristics

| Characteristics                  | n = 328 |
|----------------------------------|---------|
| Sex: female, n (%)               | 75 (22.9) |
| Age (y)                          | 70.2 (9.5) |
| Ischemic cardiomyopathy, n (%)   | 119 (36.3) |
| CRT-D, n (%)                     | 211 (64.3) |
| NYHA class, n (%)                |         |
| II                               | 79 (24.1) |
| III                              | 230 (70.1) |
| IV                               | 19 (5.8) |
| Diabetes Mellitus, n (%)         | 77 (23.5) |
| Atrial fibrillation, n (%)       | 123 (37.5) |
| AV node ablation, n (%)          | 23 (7.0) |
| Creatinine (mg/dl)               | 1.3 (0.6) |
| Hemoglobine level (g/dl)         | 13 (2.0) |
| Coronary sinus vein, n (%)       |         |
| Anterior                         | 74 (22.6) |
| Lateral                          | 170 (51.8) |
| Posterior                        | 84 (25.6) |
| QRS duration (ms)                | 162 (26.0) |
| QRS morphology, n (%)            |         |
| LBBB                             | 198 (60.4) |
| RBBB                             | 23 (7.0) |
| IVCD                             | 39 (11.9) |
| RVP                              | 68 (20.7) |
| Pharmacotherapy                  |         |
| BB, n (%)                        | 271 (82.6) |
| ACEI/ARB-II, n (%)               | 283 (86.3) |
| MRA, n (%)                       | 154 (47.0) |
| Echocardiographic parameters     |         |
| LVESV (mL)                       | 215 (64) |
| LVEDV (mL)                       | 156 (55) |
| LVEF (%)                         | 28 (8) |
| Mitral regurgitation             |         |
| 0                                | 13 (4.0) |
| I                                | 48 (14.6) |
| II                               | 85 (25.9) |
| III                              | 182 (55.5) |
| Left atrial volume (mL)          | 72 (15) |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB-II, angiotensin II receptor blockers; AV, atrio ventricular; BB, beta-blockers; CRT-D, cardiac resynchronization therapy - defibrillator; IVCD, intraventricular conduction delay; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; RBBB, right bundle branch block; RVP, right ventricular pacing.
The increases in LVEF greater than 5% and reductions in LVESV greater than 15% were associated with a reduction in mortality risk (Figure 2). Table 2 shows the variables associated with changes in LVEF and LVESV during follow-up. The largest reduction in LVESD occurred in patients with LBBB (left bundle branch block), and the smallest reduction in patients with advanced functional class (NYHA IV class). The smallest increase in LVEF was observed in patients with ischemic etiology, longer QRS and location of the VI lead in a nonlateral vein of coronary sinus. Figure 3 shows the changes of the LVEF and LVESV along time after adjusting by potential confounding variables.

3.5 | Joint modeling analysis

A survival prediction model has been carried out over time adjusted on age, sex, and changes of LVEF over time using the joint modeling methodology. Table 3 shows the relative risks with their corresponding confidence intervals. The analysis showed that the increase in LVEF after CRT was associated with higher survival rates. Male sex and older age were associated with a worse prognosis.

4 | DISCUSSION

This study provided a real-world registry to evaluate the long-term effect of CRT on LV reverse remodeling assessed by longitudinal LV structural and functional measurements over time in HF patients. CRT promotes a greater degree of reverse remodeling during the first year postimplant that is slightly enhanced in the long-term follow-up, especially in patients of female and nonischemic etiology. Moreover, variations of LV remodeling over time, analyzed using mixed models, have allowed us to improve the identification of reverse remodeling predictors. The main factors independent for predicting the improvement of LVEF have been the nonischemic etiology, higher duration of baseline QRS, and location of the LV lead in the lateral vein of the coronary sinus. The main factor for the prediction of the reduction of LVESV has been the presence of LBBB. Finally, the longitudinal changes in LVEF at follow-up improves the prediction of the mortality risk after adjusting for age and sex, by using the joint modeling analysis. To our knowledge, this is the first time to describe the effect of CRT on LV remodeling in a real-world registry. Our results have several implications, on the one hand, we describe the temporal evolution of cardiac morphology and function after CRT in a contemporary cohort of patients at follow-up. On the other hand, we showed that the effect of CRT is observed in the long term, but especially in the first year. So it would be essential to optimize pharmacological treatment during this period in order to obtain the greatest benefit early, especially in patients with a worse response profile to CRT.

Reverse remodeling is one of the hallmark findings of CRT studies in mild and advanced HF patients. So far, there are few data on the mid- and long-term of the ventricular remodeling. It was well
established the effect in the first 6-12 months after CRT. This was assessed in randomized clinical trials, that showed that CRT added to standard pharmacological therapy for HF, causes a sustained improvement in LV geometry and function in the first months after CRT. This was assessed in randomized clinical trials, that showed that CRT added to standard pharmacological therapy for HF, causes a sustained improvement in LV geometry and function in the first months after CRT. In patients with HF, pharmacological agents and CRT reduce the mortality and morbidity, also improve the geometry and function of the LV. Reverse ventricular remodeling was first evaluated in the PATH-CHF study at 12 months later to the implant and from there multiple studies have assessed the echocardiographic response to CRT and determined what characteristics could influence the reverse remodeling.21

Nowadays, the assessment of left ventricular remodeling after CRT is determined with the reduction of LVESV ≥ 15% or the increase in the absolute value of LVEF ≥ 5% at 6-12 months. It is well established that the LV remodeling induced by CRT has been related to the improvement of the quality of life, functional class, reduction of mortality, and HF hospitalizations.22,23 Most clinical trials have evaluated the LV remodeling during the 6-12 months after CRT implantation. But so far, there is little evidence of the effect of CRT on LV remodeling during longer term follow-up in real-world. This study describes for the first time in a real-world contemporary registry the long-term effect of CRT on LV remodeling.

In a sub-analysis of CARE HF trial, CRT induced sustained LV reverse remodeling in the long-term follow-up with the most marked effects occurring within the first 3-9 months. This effect may contribute to an improvement in morbidity and mortality. These beneficial effects were observed even in ischaemic patients and patients with very severe cardiac dysfunction.24 MIRACLE study investigated serial changes in LV size and function by using longitudinal data analysis in a consecutive cohort of patients with long-term follow-up. These changes were more pronounced at 6 months and remained during the long-term, but they became much less pronounced. Besides, patients with an uneventful survival demonstrated a greater decrease in the LVESV compared with patients with adverse events. Factors associated with less reverse remodeling were ischemic etiology, male sex, and QRS duration <140 ms.25 Similarly, the reverse LV

| Variable                      | Coefficient | Standard error | P-value |
|-------------------------------|-------------|----------------|---------|
| Mixed model LVEF              |             |                |         |
| Male                          | -2.096      | 1.64           | .2019   |
| Age (y)                       | 0.013       | 0.07           | .8495   |
| Ischemic cardiomyopathy       | -3.09       | 1.398          | .0275   |
| NYHA class                    |             |                |         |
| III                           | -2.137      | 1.529          | .1628   |
| IV                            | -0.826      | 3.018          | .7843   |
| AF                            | -1.095      | 1.365          | .4228   |
| LBBB                          | 1.367       | 1.341          | .3084   |
| QRS duration                  | -0.068      | 0.025          | .0069   |
| Coronary sinus vein           |             |                |         |
| Lateral                       | 3.458       | 1.715          | .0443   |
| Posterior                     | 3.514       | 1.969          | .0648   |
| Intercept                     | 22.907      | 6.328          | .0003   |
| Mixed model LVESV             |             |                |         |
| Male                          | 6.119       | 4.766          | .1999   |
| Age (y)                       | -0.064      | 0.193          | .7409   |
| Ischemic cardiomyopathy       | 7.005       | 4.053          | .0848   |
| NYHA class                    |             |                |         |
| III                           | 6.839       | 4.016          | .0894   |
| IV                            | 31.88       | 10.463         | .0025   |
| AF                            | 2.397       | 3.833          | .5321   |
| LBBB                          | -7.923      | 3.809          | .0382   |
| QRS duration                  | 0.075       | 0.076          | .3222   |
| Coronary sinus vein           |             |                |         |
| Lateral                       | -6.481      | 5.549          | .2435   |
| Posterior                     | -10.419     | 6.052          | .086    |
| Intercept                     | -37.678     | 18.029         | .0373   |

TABLE 3 Multivariable Analysis (Joint model) for mortality in HF patients after TRC during long-term follow-up

| Variable          | Coefficient (SE) | HR (CI 95%) |
|-------------------|------------------|-------------|
| Age (y)           | 0.05 (0.01)      | 1.05 (1.03-1.07) |
| Male              | 0.57 (0.23)      | 1.57 (1.12-2.77) |
| LVEF, % (∆)       | -0.03 (0.01)     | 0.97 (0.95-0.98) |

Abbreviations: CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; SE, standard error; ∆, changes.

FIGURE 3 Evolution of the change of LVESV (A) and LVEF (B) adjusted for confounding variables over time (LVEF: P < .001 with 2.42 degrees of freedom; LVESV: P < .001 with 2.45 degrees of freedom)
remodeling of CRT in a sub-analysis of REVERSE trial was sustained over 5 years. The functional and LV remodeling improvements were maximal after 2 years and were accompanied by very low mortality and HF hospitalization, although the largest change in LV volumes was noted in the first year with further remodeling.26

We show for the first time in a registry of real-world patients the variation of echocardiographic measures over time and factors involved in their variations long-term follow-up. One of the main findings is the maintaining of a favorable evolutionary profile over years after the first year when the most LV reverse remodeling was observed. We observed better ventricular remodeling in women, nonischemic etiology, LBBB morphology, and LV lead in a lateral vein of the coronary sinus similar with randomized CRT trials. We have also observed that the evolutionary patterns of LVEF and LVESV have been very heterogeneous, due to both the individual characteristics of each patient, the location and type of lead in the coronary sinus and intercurrent processes that they could appear in the natural history of HF. These could be explained because more than a quarter of patients will not present an adequate echocardiographic response, despite good patient selection.27 However, Burns et al showed that the time course of improvements in LV size and function after the initiation of CRT can evidence a slower and delayed positive CRT response after 6–12 months of therapy.28 These findings could also explain the maintaining of the long-term ventricular remodeling that we have observed in our work. Furthermore, after CRT implantation there could be a hemodynamic improvement and thus a greater prescription of well-evidence-based treatments. Then, the synergistic effect of CRT and pharmacological treatment could improve structural remodeling during follow-up. Besides, we have established, through dynamic prediction models, the individualized probability of patient survival through changes in LVEF with repeat measurements over time. This provides more information on mortality risk than a single determination of LVEF after implantation of CRT, after adjusting by age and sex. In our sample, the survival individually prediction through the models of dynamic prediction with repeated measurements of LVEF in follow-up, could help to identify patients at higher risk who require closer monitoring, optimization of drug treatment and/or management of comorbidities. These models are probably the future of personalized medicine and could allow to establish computational algorithms of response to CRT that allow prediction what is the individual risk of both mortality and cardiovascular events at a specific time during follow-up of each patient.

5 | LIMITATIONS

The retrospective nature of this analysis conducted at a single center is a potential weakness. As a consequence, the patient sample size was limited. This is an observational registry with their inherent limitations (eg selection bias, unmeasured bias), and thus associations may be confounded by unmeasured variables. Several unmeasured confounders or details about physician or patient decision-making might not be available in our collection data protocol and could account for some of the reported findings. Also, there may have been appropriate contraindications to adjunctive pharmacotherapy that were not collected. In addition, during the echocardiographic follow-up, patients who died are excluded from the analysis and this can be a positive bias because only surviving patients were included in the analysis. Finally, long-term outcomes could be modified by many circumstances that might not be available or controlled in the follow-up protocol of our center. As such, the results presented in this analysis should be considered hypothesis-generating and deserve confirmation in other registries and clinical trials.

6 | CONCLUSIONS

Reverse remodeling of the left ventricle is observed especially in the first year after CRT implantation and this effect is maintained a long time in a contemporary cohort of patients. Longitudinal LVEF measurements throughout the follow-up could predict better the individual mortality risk adjusting for potential confounding variables.

CONFLICT OF INTEREST

The authors declare no conflict of interests for this article.

ORCID

Belén Alvarez-Alvarez https://orcid.org/0000-0003-0851-7728
Moisés Rodríguez-Mañero https://orcid.org/0000-0001-7566-9321
Laila González-Melchor https://orcid.org/0000-0002-4065-221X
Francisco Gude https://orcid.org/0000-0002-9681-1662

REFERENCES

1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385:812–24.
2. Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep. 2017;19:71.
3. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. for the MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac Resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53.
4. Bristow MR, Saxon LA, Boehmer J, et al. for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. N Engl J Med. 2004;350:2140–50.
5. Cleland J, Daubert J, Erdmann E, et al. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
6. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. for the MADIT-CRT Trial Investigators. Cardiac Resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329–38.
7. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. for the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.
8. Linde C, Abraham WT, Gold MR, et al. for the REVERSE (ReSynchronization reVeRses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–43.

9. Ponikowski P, Voors A, Anker S, on behalf of Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–00.

10. Stellbrink C, Breithardt OA, Franke A, et al. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol. 2001;38:1957–65.

11. Duncan A, Wait D, Gibson D, et al. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub study of the MUSTIC (Multisite Stimulation in Cardiomyopathies) trial. Eur Heart J. 2003;24:430–41.

12. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. for the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–90.

13. Abraham WT, Young JB, Leon AR, et al. on behalf of the Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–8.

14. Chung E, Leon A, Tavazzi L, et al. Results from the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.

15. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–00.

16. Baxx JJ, Bleecker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2004;44:1834–40.

17. Zhang Y, Gualler E, Blasco-Co商用车 E, et al. Changes in follow-up left ventricular ejection fraction associated with outcomes in primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy device recipients. J Am Coll Cardiol. 2015;66:524–31.

18. Cheng J, Edwards LJ, Maldonado-Molina MM, et al. Real longitudinal data analysis for real people: buildings a good enough mixed model. Stat Med. 2010;29:504–20.

19. Rizopoulos D. Joint Models for Longitudinal and Time-to-Event Data: With Applications in R. Boca Raton: Chapman and Hall/CRC Press; 2012.

20. R Core Team. R: A Language and Environment for Statistical Computing (Computer Program). Viena, Austria: R Foundation for Statistical Computing. Disponible en; 2020. https://www.r-project.org

21. Aurichio A, Stellbrink C, Sack S, et al. The pacing therapies for congestive heart failure (PATH-CHF) study: rationale, design, and endpoints of a perspective randomized multicenter study. Am J of Cardiol. 1999;83:130–5.

22. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Develop in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15:1070–18.

23. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547–55.

24. Ghio S, Freemantle N, Scelsi L, et al. Long-term ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF. Eur. J. Heart Fail. 2009;11:480–8.

25. Verhaert D, Grimm RA, Puntawangkoon C, et al. Long-term reverse remodeling with cardiac resynchronization therapy. J Am Coll Cardiol. 2010;55:1788–95.

26. - Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-years results from the RESynchronization reVerses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592–99.

27. Daubert C, Behar N, Martins RP, et al. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017;38:1463–72.

28. Burns KV, Gage RM, Curtin AE, et al. Long-term echocardiographic response to cardiac resynchronization therapy in initial non-responders. JACC Heart Failure. 2015;12:990–7.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.